TORONTO, June 25 /CNW/ - Theralase Technologies Inc. (TSX-V: TLT) today
announced that Michel LeBel has resigned from the Board of Directors and
Andrew Szonyi has withdrawn his nomination to the Board of Directors. Both Mr.
LeBel and Mr. Szonyi joined Theralase's Board in May 2006. The Company is
currently looking to add members to its Board of Directors.
"We thank Michel and Andrew for their commitment to Theralase over the
past two years and wish them well in the future," said Donald Moore, Chairman
of Theralase's Board of Directors.
Theralase Technologies Inc. designs, develops and manufactures patented,
super-pulsed laser technology used in a wide range of bio-stimulation and
bio-destruction clinical applications. The Theralase technology platform
targets several diverse healthcare sectors: firstly, for non-invasive pain
management and clinical therapy, in hundreds of neural muscular skeletal
conditions, including arthritis; secondly, to bio-stimulate and accelerate
wound care and healing, including bone fracture regeneration; and thirdly,
combining photodynamic compounds with super-pulsed, biofeedback laser
technology to attack specifically targeted cancer, bacteria, viruses and fat
This press release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation
to update these forward-looking statements.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the contents of this
For further information:
For further information: Roger White, President & CEO, Toll Free:
1-866-THE-LASE (843-5273), Phone: (416) 447-8455, e-mail:
email@example.com; Vanessa Beresford, The Equicom Group, Phone: (416)
815-0700 ext 227, e-mail: firstname.lastname@example.org